Relationship of Vancomycin Minimum Inhibitory Concentration to Mortality in Patients With Methicillin-Resistant Staphylococcus aureus Hospital-Acquired, Ventilator-Associated, or Health-care-Associated Pneumonia

Outcomes and Treatment of Chronic Methicillin-ResistantStaphylococcus aureusDiffers by Staphylococcal Cassette Chromosomemec(SCCmec) Type in Children With Cystic Fibrosis

“…Bacterial factors related to S aureus type with potential impact include antibiotic susceptibilities, virulence factors, or bacterial fitness. Although some non-CF studies show that a higher vancomycin minimal inhibitory concentration has been associated with worse outcomes [31], we did not see vancomycin-resistant or vancomycin-intermediate isolates in this study [22]. Other bacterial factors were not assessed in this study and would only be speculative.…”

The Effects of Obesity on the Comparative Effectiveness of Linezolid and Vancomycin in Suspected Methicillin-Resistant Staphylococcus aureus Pneumonia

“…Some studies suggest patients with MRSA infections are more likely to experience clinical success with vancomycin if the vancomycin MIC is < 1 μg/mL as compared to patients with higher MICs [35,36]. In an observational study of 158 patients with hospital-acquired, ventilator-associated or healthcareassociated MRSA pneumonia, mortality increased as a function of the vancomycin MIC [37]. The overall all-cause 28-day mortality rate in these patients was 32.3%, with the majority of isolates having a vancomycin MIC ≥ 1.5 μg/mL (115/158, 72.8%) [37].…”

“…In an observational study of 158 patients with hospital-acquired, ventilator-associated or healthcareassociated MRSA pneumonia, mortality increased as a function of the vancomycin MIC [37]. The overall all-cause 28-day mortality rate in these patients was 32.3%, with the majority of isolates having a vancomycin MIC ≥ 1.5 μg/mL (115/158, 72.8%) [37]. However, a recent meta-analysis examining the association between vancomycin MIC and mortality rates in patients with Staphylococcus aureus bacteremia demonstrated no significant differences in mortality between patients with lower-vancomycin MICs (< 1.5 μg/mL) and those with higherMICs (≥ 1.5 μg/mL) [38].…”

A novel treatment option for MRSA pneumonia: ceftaroline fosamil-yielding new hope in the fight against a persistent infection

“…Respiratory complications, ICU admissions and death are all consequences of untreated MRSA pneumonia infection. The mortality for treated MRSA pneumonia is high, with mortality rates of up to 32.3% from earlier studies [7].…”